TB 600
Alternative Names: TB-600Latest Information Update: 07 Sep 2022
Price :
$50 *
At a glance
- Originator TrueBinding
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 06 Sep 2022 Discontinued for Unspecified indication in USA (unspecified route) (TrueBinding pipeline, September 2022)
- 01 Jan 2022 TrueBinding has over twenty patent applications in its portfolio protecting discoveries and their utility (TrueBinding website, December 2021)
- 15 Dec 2021 Early research in Unspecified in USA (unspecified route) (TrueBinding pipeline, December 2021)